Resistance to alpha interferon therapy in HCV chronic liver disease: Role of hepatic fibrosis

Italian Journal of Gastroenterology

Volumn 28, Issue 3, 1996, Pages 140-146

  Di Costanzo, G G ^a   Ascione, A ^a,b   Lanza, A Galeota ^a   De Luca, M ^a   Bracco, A ^a   Lojodice, D ^a   Marsilia, G Marino ^a   Ferbo, U ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Chronic liver disease; Hepatic fibrosis; Interferon; Laminin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; LAMININ;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; BIOCHEMISTRY; BLOOD LEVEL; CHRONIC HEPATITIS; CONNECTIVE TISSUE; DOSE RESPONSE; DRUG EFFICACY; EXTRACELLULAR MATRIX; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIVARIATE ANALYSIS;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMININ; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 0029892536     PISSN: 03920623     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Tinè F, Magrin S, Craxì A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A metanalysis of randomised clinical trials. J Hepatol 1991; 13: 192-9.
2. Saracco G, Rosina F, Torrani Cerenzia MR, Lattore V, Chiandussi L, Gallo V, et al. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11 (suppl 1): S43-S49.
3. Cimino L, Nardone G, Citarella C, Perna E, Capuano G, Budillon G. Treatment of chronic hepatitis C with recombinant interferon alfa. Ital J Gastroenterol 1991; 23: 399-402.
4. Battezzati PM, Podda M, Bruno S, Zuin M, Crosignani M, Camisasca M, et al. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. Ital J Gastroenterol 1992; 24: 481-4.
5. Cammà C, Craxì A, Tinè F, Almosio P, Di Marco V, Lo Iacono O, et al. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients. Hepatology 1992; 16: 131A.
6. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17: 390-6.
7. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76: 710-9.
8. Rojkind M, Dunn MA. Hepatic fibrosis. Gastroenterology 1979; 76: 849-63.
9. Villeneuve JP, Huet PM. Microcirculatory abnormalities in liver diseases. Hepatology 1987; 7: 186-7.
10. Bissel DM, Arenson DM, Maher JJ, Roll FJ. Support of cultured hepatocytes by a laminin-rich gel: evidence for a functionally significant subendothelial matrix in normal rat liver. J Clin Invest 1987; 79: 801-12.
11. Ascione A, Di Costanzo GG. Alpha-interferon in the therapy of liver disease: what future? From: "Lymphoblastoid Interferon. Current aspects and future perspectives". In: F Dianzani. Proceedings of the First International Symposium on Lymphoblastoid alpha-interferon. Curr Med Lit 1993: suppl. 43-50.
12. Biagini G, Ballardini G. Liver fibrosis and extracellular matrix. J Hepatol 1989; 8: 115-124.
13. Hahn EG. Blood analysis for liver fibrosis. J Hepatol 1984; 1: 67-73.12.
14. Schuppan D. Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis. J Hepatol 1991; 13 (Suppl. 3): S17-S25.
15. Knodell RG, Kamal G, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
16. Degott C, Giostra E, Chevallier M. Effets de l'interféron alpha sur les lésions histologiques de l'hépatite chronique C: recherche de lésions prédictives de la réponse au traitement. Gastroenterol Clin Biol 1991; 15: 895.
17. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
18. Chemello L, Pontisso P, Rose KA, Simmonds P, Bonetti P, Cavalletto L, et al. The TVVH study group. The long term response (LTR) to interferon alpha (IFN-2α) in chronic hepatitis C is influensed by dose and duration of treatment and by HCV serotype. J Hepatol 1993; 18(suppl. 1) S10.
19. Kanai K, Kato M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
20. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinat interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
21. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alfa-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7.
22. Saez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, et al. High dose of recombinant alfa-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991; 13: 327-31.
23. Ideo G, Bellati G, Pedraglio E, Leandro G. One year therapy of non-A, non-B/C chronic hepatitis with recombinant alpha-2α interferon (r-IFN) or lymphoblastoid alpha interferon (1-IFN). J Hepatol 1990; 11 (suppl. 2): S31.
24. Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990; 11 (suppl. 1): S63-67.
25. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. J Clin Pathol 1978; 31: 395-414.
26. Schaffner F, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239-42.
27. McGuire RF, Bissel DM, Boyles J, Roll FJ. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology 1992; 15: 989-97.
28. Reid LM, Fiorino AS, Sigal SH, Brill S, Holst PA. Extracellular matrix gradients in the space of Disse: relevance to liver biology. Hepatology 1992; 15: 1198-203.
29. Martinez-Hernandez A, Martinez J. The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis. Hepatology 1991; 14: 864-74.
30. Hahn EG, Schuppan D. Ethanol and fibrogenesis in the liver. In: Seitz HK, Kommerell B, eds. Alcohol-Related Diseases in Gastroenterology. Berlin: Springer, 1985; 124-53.
31. Galambos MR, Collins DC, Galambos JT. A radioimmunoassay procedure for type III procollagen: its use in the detection of hepatic fibrosis. Hepatology 1985; 5: 38-42.
32. Schuppan D, Dumont JM, Kim KY, Hennings G, Hahn EG. Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental cirrhosis. J Hepatol 1986; 3: 27-37.
33. Savolainen ER, Brocks D, Ala-Kokko L, Kivirikko KI. Serum concentration of the N-terminal propeptide of type III procollagen and two type IV collagen fragments and gene expression of the respective collagen types in liver rats with dimethylnitrosamine-induced hepatic fibrosis. Biochem J 1988; 249: 753-9.
34. Ruwart MJ, Wilkinson KF, Rush BD, Vidmar TJ, Peters KM, Henley KS, et al. The integrated value of serum procollagen type III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis. Hepatology 1989; 10: 801-6.
35. Castilla A, Pietro J, Fausto N. Transforming growth factors beta 1 and alfa in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324: 933-40.
36. Beck K, Hunter I, Hengel J. Structure and function of laminin: anatomy of a multidomain glycoprotein. FASEBJ 1990; 4: 148-60.
37. Hahn EG, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin and fibronectin. Gut 1980; 21: 63-71.
38. Clement B, Rescan PY, Baffet G, Loreal O, Lehri D, Campion JP, et al. Hepatocytes may produces laminin in fibrotic liver and in primary culture. Hepatology 1988; 8: 794-803.
39. Orrego H, Medline A, Blendis LM, Rankin JG, Kreaden DA. Collagenisation of the Disse space in alcoholic liver disease. Gut 1979; 20: 673-9.
40. Gressner AM, Tittor W, Negwer A, Pick-Kober KH. Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver disease. Clin Chim Acta 1986; 161: 249-58.
41. Soloway RP, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Dig Dis Sci 1971; 16: 1082-6.
42. Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis. Diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983; 18: 27-32.
43. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; i: 523-25.
44. Caporaso N, Suozzo R, Morsico F, D'Antonio M, Romano M, Coltorti M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: comparison of 3 or 6 MU for 1 year. It J Gastroenterol 1993; 25: 482-6.
45. Ascione A, De Luca M, Canestrini C, Amitrano L, Gigliotti T, Addario L, et al. Three versus six MU interferon (IFN) alfa 2b in the therapy of HCV-related chronic liver disease: randomized multicenter study. Hepatology 1994; 20 (Pt. 2): 155A.